पेटेंट कार्यालय शासकीय जर्नल

OFFICIAL JOURNAL OF THE PATENT OFFICE

निर्गमन सं. 22/2024 ISSUE NO. 22/2024

शुक्रवार FRIDAY दिनांक: 31/05/2024 DATE: 31/05/2024

पेटेंट कार्यालय का एक प्रकाशन PUBLICATION OF THE PATENT OFFICE (19) INDIA

(22) Date of filing of Application :27/05/2024

(43) Publication Date : 31/05/2024

(54) Title of the invention : A NOVEL COPPER-BASED METAL-ORGANIC FRAMEWORK FOR TARGETED CISPLATIN DELIVERY IN BREAST CANCER THERAPY

(51) International classification (86) International Application No Filing Date (87) International Publication No (61) Patent of Addition to	:A61P0035000000, A61K0033243000, A61K0035280000, A61K0031704000, A61K0031282000 :NA :NA :NA	(71)Name of Applicant: 1)HOLY CROSS COLLEGE (AUTONOMOUS), NAGERCOIL Address of Applicant: HOLY CROSS COLLEGE (AUTONOMOUS), NAGERCOIL,Roch Nagar, Kurisady, Nagercoil, Tamil Nadu- 629004, India NAGERCOIL Name of Applicant: NA Address of Applicant: NA (72)Name of Inventor: 1)Miss. A.H. HATIN BETSEBA
Application Number Filing Date	:NA	Address of Applicant :Department of Chemistry Holy Cross College (Autonomous), Nagercoil NAGERCOIL
(62) Divisional to Application Number Filing Date	:NA :NA	2)DR. Y. CHRISTABEL SHAJI Address of Applicant :Assistant Professor Department of Chemistry Holy Cross College (Autonomous), Nagercoil NAGERCOIL

(57) Abstract:

The present invention relates to a targeted drug delivery system for breast cancer treatment, utilizing a copper-based metal-organic framework (Cu-based MOF) synthesized from copper chloride hexahydrate and pyridine 2,6 dicarboxylic acid. The Cu-based MOF is infused with cisplatin, a widely used anticancer drug, through a simple impregnation method. The system targets explicitly breast cancer cells (MDA-MB-231), enhancing therapeutic efficacy while minimizing side effects. Key features include the Cu-based MOF's high stability and large surface area, enabling efficient drug encapsulation and controlled release. The invention offers a novel, effective, and safer alternative for cancer therapy, significantly improving traditional chemotherapy by reducing systemic toxicity and improving patient outcomes. This innovative approach is scalable, cost-effective, and adaptable for various cancer treatments.

No. of Pages: 29 No. of Claims: 11